Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorMeyerowitz, Eric A
dc.contributor.authorScott, Jake
dc.contributor.authorRichterman, Aaron
dc.contributor.authorMale, Victoria
dc.contributor.authorCevik, Muge
dc.date.accessioned2024-02-14T13:30:02Z
dc.date.available2024-02-14T13:30:02Z
dc.date.issued2024-02
dc.identifier298493921
dc.identifier8c31729b-fc45-4858-989b-de580b2ee497
dc.identifier38114838
dc.identifier85180185605
dc.identifier.citationMeyerowitz , E A , Scott , J , Richterman , A , Male , V & Cevik , M 2024 , ' Clinical course and management of COVID-19 in the era of widespread population immunity ' , Nature Reviews Microbiology , vol. 22 , pp. 75-88 . https://doi.org/10.1038/s41579-023-01001-1en
dc.identifier.issn1740-1526
dc.identifier.otherJisc: 1637114
dc.identifier.otherpii: 10.1038/s41579-023-01001-1
dc.identifier.urihttps://hdl.handle.net/10023/29235
dc.description.abstractThe clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in humans. The current high levels of population immunity, due to prior infection and/or vaccination, have been associated with a vastly decreased overall risk of severe disease. Some people, particularly those with immunocompromising conditions, remain at risk for severe outcomes. Through the course of the pandemic, variants with somewhat different symptom profiles from the original SARS-CoV-2 virus have emerged. The management of COVID-19 has also changed since 2020, with the increasing availability of evidence-based treatments in two main classes: antivirals and immunomodulators. Selecting the appropriate treatment(s) for patients with COVID-19 requires a deep understanding of the evidence and an awareness of the limitations of applying data that have been largely based on immune-naive populations to patients today who most likely have vaccine-derived and/or infection-derived immunity. In this Review, we provide a summary of the clinical manifestations and approaches to caring for adult patients with COVID-19 in the era of vaccine availability and the dominance of the Omicron subvariants, with a focus on the management of COVID-19 in different patient groups, including immunocompromised, pregnant, vaccinated and unvaccinated patients.
dc.format.extent606757
dc.language.isoeng
dc.relation.ispartofNature Reviews Microbiologyen
dc.subjectRA0421 Public health. Hygiene. Preventive Medicineen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectACen
dc.subject.lccRA0421en
dc.titleClinical course and management of COVID-19 in the era of widespread population immunityen
dc.typeJournal itemen
dc.contributor.institutionUniversity of St Andrews. Infection and Global Health Divisionen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.identifier.doi10.1038/s41579-023-01001-1
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record